The Medical Letter on Drugs and Therapeutics
Off-Label Use of Ketorolac for Athletic Injuries
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Recent reports indicate that intramuscular (IM) injection of the nonsteroidal anti-inflammatory drug (NSAID) ketorolac (Toradol, and others), sometimes directly into injured muscles, has become a common practice in US locker rooms.1

KETOROLAC — A non-selective NSAID available for oral, intranasal, IM or IV administration, ketorolac is approved by the FDA for short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. It has shown to be as effective as morphine or meperidine (Demerol, and others); 30 mg of ketorolac IM, the usual analgesic dose for continued use, is considered comparable to 12 mg of morphine, but with a longer duration of action (about 5-6 hours).2 Single-dose injections may be with 60 mg. The maximum daily dosage for adults ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Off-Label Use of Ketorolac for Athletic Injuries
Article code: 1390a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian